



Industry: Regenerative Medicine

Management:

Atsuo Ochi, PhD
(Stem Cell and Immunology) –
Founder & CEO
Seeking to Fill Additional Roles:

Chief Scientific Officer
Postdoctoral Fellows (2)
Chief Financial Officer
Chief Business Officer
Chief Legal Officer

Business Advisory Board:
Seeking Members

Scientific Advisory Board:
Seeking Members

Number of Employees: 1

Finance:
Accounting / H&R BLOCK

Funding to Date:
Founder: \$150,000

Financing Sought: \$2.0M
For:

IP Protection
Preclinical research
Business operation
Regulatory Strategy
Partnerships &
Marketing

IP:
Pat. 17,775,801 Pending to
USA, EU, JAP

Legal:
HALEY GUILIANO LLP

Business Description / Company Background :

CytoPropago is a biotech startup focused on developing proprietary technology to reprogram autologous cells into pluripotent stem cells, enabling the creation of autologous stem cell-based therapies. Our mission is to advance the future of safe regenerative medicine by addressing the growing demand for safe stem cell therapies and pioneering next-generation cell-reprogramming technologies.

Market Opportunity / Unmet Need :

Over 10 million people in the USA could benefit from regenerative therapies, with one in three individuals potentially facing health conditions where stem cell therapy could enhance their quality of life. The regenerative medicine market, valued at USD 42.18 billion in 2024, is projected to grow from USD 51.65 billion in 2025 to USD 413.29 billion by 2032, driven by increasing demand for innovative treatments. Current stem cell therapies often rely on embryonic cells or induced pluripotent stem cells (iPSCs). While the former raises ethical concerns, iPSCs are susceptible to gene mutations that heighten cancer risk and can be subject to immune rejection. These challenges underscore a significant unmet need in regenerative medicine.

Products / Services :

For the first time, CytoPropago's technology enables the generation of autologous, mutation-free reprogrammed cells for use in treating diseases. When combined with recent advances that reduce the cost and complexity of large-scale production, this technology has the potential to significantly accelerate the field of regenerative medicine. The company plans to establish licensing and collaboration agreements with established pharma and biotech companies focused on specific diseases or indications. These partnerships, leveraging the infrastructure and capabilities of industry leaders, will facilitate the rapid development and market introduction of regenerative cell therapies.

Commercial / Technical Milestones :

CytoPropago will focus on refining its reprogramming technology, filing patents, and publishing research in peer-reviewed journals to increase the technology's credibility. Key milestones include filing patents for the current and enhanced reprogramming methods in Europe, Japan, and the USA within 12–18 months, as well as publishing research within 8–10 months.

Competition / Competitive Advantages/Customer Benefits :

For over a decade, numerous companies have explored iPSC technology-based cell therapies, yet challenges related to inherited gene mutations and allogenic origins remain unresolved. Unlike current reprogramming methods, which modify gene expression through exogenous gene introduction, CytoPropago's approach harnesses the cell's endogenous programming, producing mutation-free cells. This innovation offers a safer, more sustainable solution for patients, positioning CytoPropago to lead the regenerative medicine market.

Financial Forecast :

CytoPropago seeks funding to support product development, collaborations, expansion of patent portfolio, and publishing efforts. The success of these activities will establish the company as a leader in autologous induced pluripotent stem cell-based cell therapy area.

	2025	2026	2027	2028	2029
Revenue (in 1000s)	\$100	\$250	\$450	\$900	\$1800
Growth Rate		250%	180%	100%	100%
Gross Profit	\$66	\$187.5	\$360	\$810	\$1620
Gross Margin	66%	75%	80%	90%	90%